AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions. Its research and rigorous atrial fibrillation clinical trials have led to innovations in ablation technology to treat atrial fibrillation with lasting solutions. Synergy Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of persistent atrial fibrillation and longstanding persistent atrial fibrillation in patients undergoing open heart procedures simultaneously. AtriCure also pioneered the AtriClip LAA Exclusion System. The company collaborates with surgeons to make surgeries like the Maze IV simpler to perform and be reproducible by more doctors around the world. Through continued commitment to product innovation and education grounded in clinical science, AtriCure is working to reduce the global atrial fibrillation epidemic.
Type
Public
HQ
Mason, US
Founded
2000
Size (employees)
500 (est)+17%
AtriCure was founded in 2000 and is headquartered in Mason, US

Key People at AtriCure

Michael Carrel

Michael Carrel

President & CEO
Andrew Wade

Andrew Wade

VP & CFO

AtriCure Office Locations

AtriCure has offices in Mason, West Chester, Minnetonka, San Ramon and in 22 other locations
Mason, US (HQ)
7555 Innovation Way
Amsterdam Zuidoost, NL
260 De Entree
San Ramon, US
110 2420 Camino Ramon
Minnetonka, US
250 130 Cheshire Ln
West Chester, US
6217 Centre Park Drive
Show all (26)

AtriCure Data and Metrics

AtriCure Financial Metrics

AtriCure's revenue was reported to be $155.1 m in FY, 2016 which is a 20% increase from the previous period.
USD

Revenue (FY, 2016)

155.1 m

Revenue growth (FY, 2015 - FY, 2016), %

20%

Gross profit (FY, 2016)

111.1 m

Gross profit margin (FY, 2016), %

72%

Net income (FY, 2016)

(33.3 m)

EBIT (FY, 2016)

(31.1 m)

Market capitalization (21-Jul-2017)

760.5 m

Cash (31-Dec-2016)

24.2 m

EV

760.2 m
AtriCure's current market capitalization is $760.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

81.9 m107.5 m129.8 m155.1 m

Revenue growth, %

31%21%20%

Cost of goods sold

22.3 m31.7 m36.9 m44 m

Gross profit

59.6 m75.8 m92.9 m111.1 m

Gross profit Margin, %

73%70%72%72%

R&D expense

35.8 m

General and administrative expense

106.4 m

Operating expense total

70.5 m92.1 m119.6 m142.2 m

EBIT

10.9 m(16.4 m)(26.7 m)(31.1 m)

EBIT margin, %

13%(15%)(21%)(20%)

Interest expense

566 k305 k292 k1.8 m

Interest income

16 k96 k190 k227 k

Income tax expense

18 k(33 k)(36 k)40 k

Net Income

(11.5 m)(16.2 m)(27.2 m)(33.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

14.9 m28.4 m23.8 m24.2 m

Inventories

10.2 m14.3 m17.7 m17.7 m

Current Assets

52.5 m93.5 m74.8 m85.7 m

PP&E

5.6 m11.6 m31.3 m30 m

Goodwill

35.4 m35.4 m105.3 m105.3 m

Total Assets

111.9 m158.4 m273.1 m276.4 m

Accounts Payable

8.6 m7.6 m12.7 m10.7 m

Total Debt

23.9 m

Current Liabilities

26.7 m25.6 m31.6 m28.8 m

Total Liabilities

108 m

Additional Paid-in Capital

194.9 m271.3 m352.9 m367.9 m

Retained Earnings

(122.2 m)(138.4 m)(165.6 m)(199 m)

Total Equity

72.6 m132.5 m186.7 m168.4 m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.5 x1.2 x1.5 x1.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(11.5 m)(16.2 m)(27.2 m)(33.3 m)

Depreciation and Amortization

2 m4.8 m6.3 m9.3 m

Accounts Receivable

(1.2 m)(4.2 m)(900 k)(2 m)

Inventories

(2.3 m)(4.3 m)(3 m)(79 k)

Accounts Payable

1.4 m(944 k)4 m(1.1 m)

Cash From Operating Activities

(5.2 m)(21.6 m)(7.8 m)(15.1 m)

Purchases of PP&E

(9.2 m)(13.4 m)(7.7 m)

Cash From Investing Activities

(14.2 m)(30.6 m)(10.5 m)(12.1 m)

Cash From Financing Activities

26.8 m65.9 m14 m27.7 m

Interest Paid

473 k115 k232 k1.5 m

Income Taxes Paid

30 k146 k20 k30 k
Y, 2016

EV/EBIT

-24.4 x

EV/CFO

-50.3 x

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.6 x

AtriCure Market Value History

AtriCure Job Categories

AtriCure Online and Social Media Presence

AtriCure Company Life and Culture

You may also be interested in